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Abstract
Outcomes for patients with non-Hodgkin’s lymphoma (NHL) that proves refractory to treatment remain poor. Treatment of such
patients is individualized and can include enrolment in a clinical trial of novel agents or use of one of a wide array of drug
regimens. Initial treatment with anthracyclines such as doxorubicin limits options at later stages of treatment because of
anthracycline-related cumulative cardiotoxicity. The aza-anthracenedione pixantrone was developed to reduce the likelihood
of cardiotoxicity without compromising efficacy and is currently conditionally approved for use as monotherapy in patients with
multiply-relapsed or refractory aggressive B cell NHL. The use of pixantrone in combination therapy, often to replace doxoru-
bicin or mitoxantrone, has or is currently being investigated in numerous studies in patients with aggressive or indolent NHL and
is the focus of this review. These include the R-CPOP regimen (rituximab, cyclophosphamide, pixantrone, vincristine, predni-
sone) for aggressive NHL in the first-line setting, including a study in elderly patients with limited cardiac function, and for
patients with relapsed NHL with prior anthracycline exposure; the PSHAP regimen (pixantrone, cytarabine, prednisone, cisplat-
in), also in the latter setting; the PREBen/PEBen regimen (pixantrone, bendamustine and etoposide with or without rituximab) as
salvage therapy; and pixantrone in combination with fludarabine, dexamethasone, and rituximab (FPD-R) for relapsed indolent
NHL.
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Introduction
Pixantrone is a novel aza-anthracenedione, developed to re-
duce cardiotoxicity typically associated with anthracyclines
but without compromising antineoplastic efficacy [1].
Anthracenediones contain only three planar rings versus
four of anthracyclines and also lack the daunosamine
amino-sugar that anthracyclines possess [2]. Pixantrone
has critical differences in its molecular structure compared
with the prototypic anthracenedione mitoxantrone, differ-
ences that reduce pixantrone’s cardiotoxic potential com-
pared with mitoxantrone [2]. In pixantrone, a hydroqui-
none was removed and a nitrogen heteroatom inserted in
the same ring, and (ethylamino)diethylamine side chains
were substituted for (hydroxyethylamino)ethylamino side
chains (as reviewed by Menna and colleagues [2]).
Its mechanism of action includes anthracycline-like DNA
alkylation and formation of permanent double-strand breaks
and resultant apoptosis, but recent lines of evidence suggest a
more prominent role for sequential rounds of aberrant mitosis
leading to cell death [2]. Unlike anthracyclines and
anthracenediones, it is only a weak inhibitor of topoisomerase
II [3]. Pixantrone’s novel molecular structure aimed to elimi-
nate interactions with iron, thus reducing its potential for
cardiotoxicity typically associated with anthracyclines [2].
Pre-clinical study results of pixantrone monotherapy
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suggested less cardiotoxicity compared with doxorubicin and
mitoxantrone [4–6].
The EuropeanMedicines Agency issued a conditional mar-
keting authorization for pixantrone in May 2012 based on
available clinical evidence [7]. The phase III trial of
pixantrone monotherapy (“PIX301”) in 140 adult patients
with relapsed/refractory aggressive non-Hodgkin’s
Lymphoma (NHL) confirmed its antineoplastic efficacy and
clinically acceptable toxicity profile [8, 9]. Complete response
(CR)/unconfirmed CR (uCR) [primary endpoint] and overall
response rates (ORRs) were significantly higher with
pixantrone monotherapy than physician’s choice comparator
chemotherapy regimens: 20% vs 5.7% (p = 0.021) and 37.1%
vs 14.3% (p = 0.003), respectively [8]. Progression-free sur-
vival (PFS) was significantly longer with pixantrone (5.3 vs
2.6 months; p = 0.005) [8]. Post hoc analyses of the subpopu-
lation of patients with relapsed/refractory aggressive B cell
NHL (n = 97) confirmed the advantage of pixantrone over
comparator regimens, and this advantage was maintained in
patients receiving pixantrone as third- or fourth-line therapy
irrespective of previous rituximab treatment (with rituximab:
pixantrone vs comparator ORR of 45% vs 11.1% p = 0.033
and PFS 5.4 vs 2.8 months, hazard ratio [HR] 0.52, 95%
confidence interval [CI] 0.26–1.04; without rituximab: ORR
of 42.1% vs 14.3%, p = 0.078; PFS 6.1 vs 3.5 months, HR
0.36, 95%CI 0.18–0.73) [9]. Pixantrone tolerability in the B
cell subpopulation post hoc analysis was concordant with re-
sults from the overall patient population, and the frequency of
cardiac adverse events (AEs) did not increase with increasing
pixantrone exposure [9]. Another post hoc analysis of the
PIX301 study investigated any possible correlations between
patient characteristics and clinical response in the 17 patients
(median age 61 years; 58.8% with diffuse large B cell lym-
phoma [DLBCL]; 70.6% had received two prior lines of ther-
apy) treated who achieved a CR or uCRwith pixantrone in the
study (24% of patients). While the majority of patients
(64.7%) who achieved a CR in this analysis had responded
(CR/partial response [PR]) to the previous line of treatment,
the achievement of a durable response appeared to be inde-
pendent of the type of response to prior therapy [10].
Pixantrone is approved for use as monotherapy in adult
patients with multiply-relapsed or refractory aggressive B cell
NHLs [3]. It is administered intravenously on days 1, 8, and
15 of a 28-day cycle for up to six cycles at a dosage of 50 mg/
m2 (base form dose) [3]. Intravenous pixantrone offers a pre-
dictable pharmacokinetic profile [11]. It displays linear phar-
macokinetics over the 3–105 mg/m2 dose range [3]. After
intravenous administration, distribution is rapid, with a
prolonged elimination phase (mean half-life approximately
23 h) [3]. It has a large volume of distribution (25.8 L) and
is approximately 50% plasma protein-bound [3]. Drug metab-
olism is limited; its primary route of excretion is as unchanged
drug in the bile [3].
Patients with indolent or aggressive NHL who are refrac-
tory to treatment or who experience multiple relapses remain
difficult to treat. Novel treatment regimens are required, and
on this basis, pixantrone has been investigated as combination
therapy in clinical studies in both aggressive [12–17] and in-
dolent [18, 19] forms of NHL. The aim of this narrative review
is to describe the current evidence for the use of pixantrone in
combination therapy in refractory/relapsed aggressive or in-
dolent NHLs, and to review ongoing studies of pixantrone in
this setting. As this is a narrative review, there was no struc-
tured search strategy.
Pixantrone in aggressive lymphomas
CPOP regimen
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vin-
cristine, prednisone), with or without radiotherapy, is a stan-
dard regimen for the first-line treatment of DLBCL, although
the specific type of R-CHOP regimen may vary according to
clinical need [20, 21]. In an effort to minimize anthracycline-
related cardiotoxicity, pixantrone (150 mg/m2 intravenously)
was used in place of doxorubicin (R-CPOP, 21-day cycle) in a
comparative, phase II, open-label study in 124 untreated adult
patients with CD20+ DLBCL [14]. Efficacy results showed
that the R-CPOP regimen (n = 61) is an active regimen and
safety results showed substantially lower cardiotoxicity than
with R-CHOP (n = 63) [14]. The CR/uCR response rate was
75% with R-CPOP versus 84% with R-CHOP. While the
study was intended to be a non-inferiority study, enrolment
was halted early due to regulatory constraints and thus the
study was underpowered to confirm the non-inferiority of R-
CPOP versus R-CHOP. Other efficacy endpoints were deter-
mined as supportive evidence and were similar between
groups: for example, median PFS was not reached in the R-
CPOP treatment arm probably due to premature study termi-
nation and was 40 months in the R-CHOP arm (HR 1.02;
95%CI 0.60–1.76; p = 0.934) [14]. The most common AEs
(≥ 10%) in both treatment arms were general and hematologic
disorders and the most common grade 3/4 drug-related AEs in
both treatment groups were neutropenia, leukopenia, lympho-
penia, febrile neutropenia, and anemia. The proportions of
patients with congestive heart failure (CHF) [0% vs 6%; p =
not significant], a decline from baseline in ejection fraction
(EF) of ≥ 20% (2% vs 17%; p = 0.004), and elevations in
troponin-T levels (7% vs 33%; p = 0.003) were lower in the
R-CPOP than R-CHOP group [14]. While non-inferiority was
not demonstrated, the cardiotoxicity results seem to support
the pre-clinical characteristics of pixantrone as compared with
doxorubicin. Study authors concluded that their results sup-
port further investigation of pixantrone as first-line therapy in
high cardiac risk DLBCL patients [14].
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Indeed, there is an ongoing open-label phase II study in
Germany and Austria of first-line R-CPOP in elderly patients
with DLBCL including in those with limited cardiac function
[EudraCT number: 2014-005069-60) [22]. Adults with DLBCL
or grade IIIB follicular lymphoma (FL) will be enrolled, in two
pre-specified subpopulations: (1) elderly patients (≥ 75 years)
not eligible for standard R-CHOP21 and (2) patients with im-
paired cardiac function (EF ≥ 40% and ≤ 50%). Preliminary re-
sults from one of the centers participating in the study (the
University Hospital Freiburg, Germany [n = 10]) suggests this
regimen is feasible and well tolerated with expected hematolog-
ical toxicities and no neutropenia-related deaths [17]. Eight pa-
tients had DLBCL, one had high-grade B cell lymphoma, and
one had Richter transformation; their median age was 72.4 years
(range 61–84) and all patients had clinical CHF at baseline.
Eight patients completed four to six cycles of R-CPOP, of whom
none experienced higher-grade acute cardiac toxicity while on
treatment [17]. Early efficacy results showed confirmed com-
plete remission in five patients and current median overall sur-
vival (OS) of 10 months (range 2–31 months) [17].
The use of an anthracycline-based regimen such as R-CHOP
in second-line treatment is limited by cumulative anthracycline-
related cardiotoxicity [12]. Pixantrone is suited for use therefore
in patients with relapsed NHL with prior anthracycline expo-
sure. Borchmann and colleagues assessed the tolerability and
potential efficacy of CPOP in a phase I/II study in adult patients
(n = 35/30) with relapsed aggressive NHL who had previously
received CHOP (with or without rituximab) and who were inel-
igible for stem cell transplantation (SCT) [12]. The majority of
patients had DLBCL or grade III FL. Pixantrone was given at
the dose determined by the phase I part of the study (150mg/m2)
in combination with fixed standard doses of cyclophosphamide
(750 mg/m2 IV) and vincristine (1.4 mg/m2 IV, not exceeding
2.0 mg), all of which were administered on day 1. Prednisone or
prednisolone (100 mg orally) was administered on days 1
through 5 in each of and up to six 21-day cycles. This regimen
gave a CR/uCR of 47% and a median CR duration of
10.5 months [12]. The ORR was 73%, and median OS was
17.9 months [12]. In the phase II part, serious AEs of grade 3
or 4 severity were hematologic AEs (70% of patients) and in-
fections (23%), and febrile neutropenia occurred in 20% of pa-
tients [12]. Small study size precluded authors from making
definitive conclusions about the cardiac safety of this regimen,
and pre-existing conditions confounded determination of cau-
sality in four patients who developed symptomatic heart failure
[12]. Study authors noted that their patients already had a mean
prior doxorubicin-equivalent drug exposure of about 300mg/m2
at baseline andmost then went on to receive six cycles of CPOP.
They suggested that the rate of clinically significant cardiac AEs
in their study could be considered lower than expected than if
their patients had instead received six cycles of CHOP [12],
based on analyses of the relationship between doxorubicin cu-
mulative dose and doxorubicin-related CHF [23].
Recent Spanish (“GELTAMO”) guidelines for the treat-
ment of patients with DLBCL mention that the results of this
CPOP trial are noteworthy when considering options for
second-line therapy in patients with relapsed DLBCL [24].
PREBEN/PEBEN regimen
Bendamustine and etoposide may be ideal candidate drugs for
use in combination with pixantrone (PEBEN) as they may act
synergistically with pixantrone [2]. This combination (with
rituximab in CD20+ tumors [PREBEN]) originally developed
by the Nordic Lymphoma Group (NLG) was first reported in
2014 [25] and consisted of pixantrone 50 mg/m2 (base form
dosage) on day 1 and day 8 plus etoposide 100 mg/m2 on day
1 plus bendamustine 90 mg/m2 on day 1, with or without
rituximab 375 mg/m2 on day 1 of a 21-day cycle (maximum
6 cycles) [13, 26].
The NLG has also used this combination (with rituximab in
CD20+ tumors [PREBEN]) in 30 heavily pretreated patients
with aggressive NHL (Table 1; data available as a poster) [13],
with their findings informing subsequent clinical trial design,
as well as by a Spanish group in five patients with refractory or
relapsed DLBCL [26]. These early results suggest that
PREBEN/PEBEN is a feasible salvage regimen, with durable
and substantial responses to treatment in individual patients
(Table 2) [13]. Additionally, there were differences in re-
sponse in the DLBCL subgroup between multiple-relapse pa-
tients and patients with refractory disease: seven of nine “frail”
patients with relapsed disease not eligible for transplant and
one of two patients with relapses post-transplant responded to
treatment whereas only one of six primary refractory patients
responded. In addition, PREBEN/PEBEN acted as bridging
therapy in patients with peripheral T cell lymphoma [PTCL]
(4 of 7 proceeded to non-myeloablative allogeneic transplant)
[13]. Similarly, positive success using PREBen/PEBen as a
bridging therapy was obtained in three of five (60%) patients
at the Spanish center who received previous chemotherapy
with multiple drugs (mean lines of treatment = 3), who
achieved objective responses after two treatment cycles, and
two of these patients experienced a CR making them eligible
for an allogeneic transplant after cycle 6 [26].
Given these encouraging results, this combination is now
being investigated in a NLG-coordinated intergroup trial in
collaboration with the HOVON group. This is an open-label
phase I/II trial investigating PREBEN/PEBEN as a salvage
regimen for heavily pretreated patients with aggressive B or
T cell lymphomas (NCT02678299, EudraCT no. 2015-
000758-39) [16, 27]. The phase I part of the study has now
been completed [16]. Patient characteristics prior to salvage
PREBEN/PEBEN are summarized in Table 1. The majority
had DLBCL and all had intermediate or high IPI risk scores.
According to pre-defined criteria, patients were subdivided
into “fit” and “frail” groups: the former entered the dose-
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finding phase I part at baseline dose level and frail patients
enter the phase II part directly, also at the same baseline dose
level [16]. The baseline treatment regimen was the same as the
regimen in the compassionate use study but with a maximum
of 4 to 6 cycles [16].
Interim efficacy results have been reported for the first 10
patients (in phase I or II) and are summarized in Table 2,
indicating that PREBEN/PEBEN is a feasible salvage regi-
men, even after only a few treatment cycles [27]. All 10 pa-
tients experienced a response to treatment and 40% had a
complete metabolic response (CMR) [27].
Five patients completed phase I, and according to the pri-
mary endpoint, the maximum tolerated dose of PREBEN is
pixantrone 50 mg/m2 day 1 and 8, etoposide 100 mg/m2 on
day 1, bendamustine 90 mg/m2 on day 1, and rituximab
375 mg/m2 on day 1 [16]. The two dose-limiting toxicities
were neutropenic infection and post-therapeutic neutropenia
(< 0.5 × 109/L) for more than 5 days in a patient without mar-
row involvement [16].
Considering the available evidence, the PREBEN/PEBEN
salvage regimen seems to be generally well tolerated. In the
observational study [13], 52% of patients experienced grade
3–4 hematologic toxicities (mainly neutropenia and thrombo-
cytopenia) and 21% grade 3–4 infections. One patient with
PTCL developed CHF but had prior doxorubicin exposure.
One patient with transformed indolent lymphoma (tIND) de-
veloped acute myeloid leukemia with therapy-related cytoge-
netic features but had previously received ibritumomab
tiuxetan. In the phase I/II study, preliminary safety data for
all 10 patients at the time of the analysis confirmed the most
common grade 3–4 toxicity to be hematologic, grade 3–4
infections were reported in two patients [27]. The Spanish-
center experience confirmed no new unexpected AEs with
PREBEN [26].
PSHAP regimen
The ESHAP (methylprednisone, etoposide, cytarabine, cis-
platin) regimen has been commonly used in the setting of
relapsed/refractory aggressive NHL [15]. Current National
Comprehensive Cancer Network (NCCN) guidelines include
this regimen among others (with or without rituximab) for
patients with relapsed or refractory DLBCL that is
chemosensitive at relapse and who are candidates for high-
dose therapy/autologous stem cell rescue (HDT/ASCR) [21].
In a phase I/II study in 19 adult patients with relapsed/
refractory aggressive NHL (mainly DLBCL) all of whom
had received prior doxorubicin, pixantrone replaced etoposide
in the ESHAP regimen (PSHAP) [15]. The PSHAP regimen
was pixantrone 80 mg/m2 (base form dose) on day 1 plus, at
fixed doses, cytarabine 2000 mg/m2 on day 5, prednisone
500 mg/m2 days 1–5, and cisplatin 25 mg/m2 on days 1–4
of a 21 day cycle [15]. All drugs were administered intrave-
nously. Efficacy results were particularly promising after a
median of four treatment cycles (CR 37%, PR 21%, ORR
58%) [15]. Six of 11 patients responding to PSHAP
underwent SCT, and thus, this regimen should be evaluated
further for reducing pre-transplant tumor burden [15].
Hematologic toxicities were considered to be clinically ac-
ceptable (Fig. 1), and only one patient developed febrile neu-
tropenia, and none died from infection or hemorrhage [15].
No clinically significant cardiac toxicity occurred. Seven pa-
tients had left ventricular ejection fraction (LVEF) decreases
from baseline (although none ≥ 19% vs baseline), which were
transient in three patients [15].
Table 1 Summary of baseline patient characteristics in preliminary
clinical experiences in Europe of the PREBen salvage regimen in
patients with relapsed aggressive B- and T cell lymphomas
Observational
study [13]
Ongoing phase I/II
trial [27]
No. of pts 30 12
Male/female 19/11 8/4
Age range, year 49–81 39–80
No. of previous chemotherapy
regimens, mean (range)
3 (1–7) 3 (1–5)
Prior ASCT, n NR 3
Histopathology, n
DLBCL 17 8
tIND 6 –
PTCL 7 4
IPI score > 2, n 30 12
ASCT autologous stem cell transplant, DLBCL diffuse large B-cell lym-
phoma, IPI International Prognostic Index, NR not reported, PREBen
pixantrone, bendamustine, etoposide, rituximab, PTCL peripheral T cell
lymphoma, tIND transformed indolent lymphoma
Table 2 Summary of preliminary efficacy results of the PREBen
salvage regimen in patients with relapsed aggressive B- and T cell
lymphomas
Observational
study ([13]) N = 30
Ongoing phase I/II
trial ([27]) N = 10a
CMR, n (%) 8 (27) 4 (40)
PMR, n (%) 7 (23) 6 (60)
ORR, n (%) 15 (50) 10 (100)
bResponse duration, month 2–23+ 4–7+
CMR complete metabolic response, ORR overall response rate, PMR
partial metabolic response, PREBen pixantrone, bendamustine,
etoposide, rituximab
aAfter 2 cycles of treatment
b Response duration data are indicative only based on time point at which
data were analyzed, rather than formal study end. + sign indicates re-
sponse was ongoing at the data cut-off point
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Pixantrone plus rituximab
The efficacy and safety of pixantrone plus rituximab (PIX +
R) was compared with gemcitabine plus rituximab (GEM+
R) in patients with aggressive relapsed or refractory B cell
NHL in the randomized, multicenter, phase III PIX 306 trial
(NCT01321541) [28, 29]. This trial was initiated to meet post-
authorization requirements because the pivotal registrational
trial of pixantrone monotherapy [8] had been designed before
rituximab became the standard of care [7, 28]. The trial en-
rolled 312 patients (median age 73 years; range 26–91) in
whom the primary efficacy endpoint of PFS was not reached.
The median PFS of 7.3 months in the PIX + R group versus
6.3 months in the GEM+R group. The median OS (13.3 vs
19.6 months) and the ORR (61.9% vs 43.9%) was also higher
in the PIX + R group compared with GEM+R group, which
also had a higher proportion of patients achieving a complete
response (35.5% vs 21.7%) [29].
Pixantrone in relapsed or refractory indolent
lymphomas
There is large diversity in the spectrum of NHL subtypes [30].
While an indolent course is described for a number of different
subtypes, the most common subtype of indolent NHL is FL,
which accounts for 22% of all newly diagnosed cases of NHL
[31]. Most patients with indolent lymphomas eventually die
after a chronically relapsing and remitting disease course [32].
There are many therapeutic options for patients with relapsed
FL: rituximab monotherapy, combination chemotherapy plus
rituximab, SCT (where appropriate), and radioimmunotherapy
[33]. Chemotherapy options include multi-agent regimens that
are platinum salts-, alkylating agents-, or fludarabine-based
[34].
Although not approved for use in patients with relapsed/
refractory indolent NHL, pixantrone has been studied in this
setting in combination with rituximab in a phase III trial [18]
and in combination with fludarabine, dexamethasone, and ri-
tuximab in a phase I study (FPD-R) [19]. The focus of this
section is on the latter dose-escalating study with an expansion
cohort, which assessed the safety and efficacy of FPD-R [19].
At the time this study was designed, FND (fludarabine,
mitoxantrone, and dexamethasone) was a standard regimen
for relapsed or refractory indolent NHL [19]. The rationale for
replacing mitoxantrone with pixantrone was pixantrone’s more
favorable cardiac toxicity profile in pre-clinical models [35],
and its efficacy in relapsed or refractory aggressive NHL [8].
The FPD-R regimen was shown to be highly active and
well tolerated in relapsed indolent NHL in a phase I dose-
escalation study [19]. Most patients enrolled in this trial had
follicular center cell lymphoma or small lymphocytic lympho-
ma. Patients received a median of 5 28-day cycles [19]. Of 27
evaluable patients, the ORR was 89%, the CR 63%, uCR 7%,
and PR 19%. Treatment response was durable, with a median
response of 23 months. The most common toxicities were
hematologic, but there was a low incidence of febrile neutro-
penia (4%). Treatment-related serious AEs were reported in
14 patients and 9 patients discontinued study treatment be-
cause of AEs (hematologic AEs [n = 4], grade1–2 decrease
in LVEF [n = 4], rash [n = 1; related to rituximab]) [19].
However, there were no grade 3–4 cardiovascular AEs or
episodes of CHF. Seven of eight patients with grade1–2 de-
creases in LVEF had previously received anthracyclines [19].
These promising safety and efficacy results of pixantrone
combination therapy for relapsed indolent NHL are supported
by results from the randomized, open-label phase III trial (n =
38) [data available as an abstract] [18]. Although the study
was discontinued earlier than expected due to low patient
enrollment, the results suggested that pixantrone plus rituxi-
mab may be more effective than rituximab monotherapy in
this patient population (ORR 75% vs 33%, CR 35% vs 11%,
PR 40% vs 22% and time to progression: 13.2 vs 8.1 months)
[18]. The combination was generally well tolerated, with only
Fig. 1 Tolerability of PSHAP
(pixantrone, cytarabine, cisplatin,
prednisone) regimen in 19
patients with relapsed/refractory
aggressive non-Hodgkin’s
lymphoma in a phase I/II dose-
escalation study [15]
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two drug-related serious AEs (febrile neutropenia [n = 2]) al-
though six patients in the combination group withdrew be-
cause of AEs (none did so in the rituximab arm) [18].
Safety and tolerability of pixantrone
Pixantrone is reported to have significant antineoplastic efficacy
with lower cardiotoxicity compared with other anthracyclines
[1]. Several mechanisms have been proposed for its limited
potential to produce cardiomyocyte damage, including its in-
ability to bind iron [36], and its greater selectivity for topoisom-
erase IIα than IIβ [37]. Evidence to date from pixantrone
monotherapy trials (as reviewed previously [35]) and the com-
bination therapy trials reviewed here tend to confirm an accept-
able safety profile in terms of cardiotoxicity. However, it re-
mains important to continue to assess cardiotoxicity in all future
trials and particularly with post marketing surveillance, which
may detect “late” cardiotoxicity [38]. Results from new studies
specifically including patients with pre-existing cardiac dys-
function (e.g., the first-line R-CPOP study [22]) are awaited
with interest in this regard.
Like other cytotoxic chemotherapies, myelosuppression is
very common with pixantrone [8, 38], and this remains the
case when given in combination therapy. Overall, there appear
to be no new or unexpected AEs when pixantrone is given in
combination therapy.
Other ongoing pixantrone combination
therapy trials
There are three ongoing studies of interest: a phase I/II trial of
pixantrone in combination with bendamustine and rituximab in
patients with relapsed/refractory aggressive B cell NHL
(NCT01491841) [39]; two non-comparative, open-label, multi-
center phase II trials, the first in patients with relapsed aggressive
B cell lymphoma are being treated with pixantrone plus the
novel type II anti-CD20 antibody obinutuzumab (GA101)
[“GOAL”; NCT02499003] [40, 41] and the second in CD20+
patients with relapsed or refractory aggressive NHL who will
receive pixantrone in combination with ifosfamide, etoposide,
and rituximab (NCT03458260) [42]. Preliminary results are
available from the multicenter, non-randomized, investigator-
initiated GOAL trial that enrolled 67 patients (median age
75 years, 55.5% female) who were treated with up to 6 cycles
of pixantrone 50 mg/m2 on days 1, 8, and 15 of each cycle and
obinutuzumab 1000 mg flat dose on day 1, 8, and 15 of cycle 1
and day 1 of each subsequent cycle. This study reported a me-
dian PFS of 82 days after a median follow-up of 8.2 months; the
median OS was not reached (both secondary endpoints) [43].
Discussion and conclusions
Treatment challenges remain in the management of relapsed
aggressive NHL as a there is a lack of regimens as effective as
first-line therapy [11]. Results from the SCHOLAR-1 retro-
spective study (n = 636), representing the largest number of
patients with refractory DLBCL included in an analysis of
response and survival rates in the rituximab-era confirms the
poor long-term outcomes of these patients (ORR 26% and
median OS 6.3 months) [44].
Pixantrone was effective as monotherapy in multiply-re-
lapsed/refractory aggressive NHL, according to results from
the PIX301 trial [8], and may be associated with durable re-
sponse and long-term remission in some patients, according to a
recent post hoc analysis of data from this trial (n = 17) [10]. On
the basis of the results of the PIX306 trial [29], the European
Medicines Agency (EMA) has recently issued a positive opin-
ion for pixantrone and converted its conditional approval into a
standard marketing authorization as a monotherapy for the
treatment of adult patients with multiply-relapsed or refractory
aggressive non-Hodgkin B cell lymphoma [45]. While patients
may remain sensitive to anthracyclines, which are often used in
first-line therapy, cumulative dose toxicity limits their use in
subsequent lines of therapy [11], and this is where pixantrone
has the potential to transform the management of patients with
relapsed aggressive disease. Multi-agent pixantrone-containing
regimens such as CPOP, PREBen/PEBEN, and PSHAP, as
reviewed here, seem to offer feasible alternatives to commonly
used regimens in the multiply-relapsed setting with no new or
unexpected AEs, although data for PREBen/PEBen are very
preliminary and further comparative prospective phase II/III
trials with these regimens would be informative.
Focus has shifted to whether pixantrone in R-CPOP
may be a novel option in the first-line setting for aggres-
sive NHL, particularly in patients with cardiac impairment
or in those not eligible for standard first-line R-CHOP21,
and a phase II trial has been initiated [22]. Data from a
previous study suggests R-CPOP is better tolerated than
R-CHOP, particularly in terms of cardiotoxicity, and this
study had included patients with a history of cardiac events
[14]. Thus, pixantrone may be particularly useful for pa-
tients who have pre-existing comorbidities which would
preclude use of anthracyclines [11].
Pixantrone has also been used in relapsed/refractory indo-
lent lymphoma as part of the FPD-R regimen [19] and in
combination with rituximab [18] and was shown to be highly
active and well tolerated. Given that fludarabine-based regi-
mens are included among the dual/multi-agent regimens rec-
ommended as salvage treatment for patients with relapsed FL,
the combination of pixantrone with rituximab and fludarabine
seems worthy of investigation [34]. Likewise, pixantrone
could replace mitoxantrone in FCM-R (fludarabine,
cyclophosphamide, mitoxantrone-rituximab) in this setting.
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In conclusion, there is accumulating evidence for the po-
tential efficacy and safety of pixantrone for use in combination
regimens for the management of relapsed/refractory aggres-
sive or indolent NHLs. Several clinical trials are ongoing, one
of which will also investigate pixantrone as first-line therapy
in the R-CPOP regimen, including in a subgroup of patients
with impaired cardiac function. As results of these trials be-
come available, the place of pixantrone as a valuable compo-
nent of combination therapy for NHL treatment may become
more firmly established.
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